Per Wold-Olsen Joins Gilead Sciences’ Board of Directors
January 28 2010 - 4:30PM
Business Wire
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that Per
Wold-Olsen has been appointed to the company’s Board of Directors,
bringing the number of directors to 13.
Mr. Wold-Olsen spent more than 30 years with the global
research-based pharmaceutical company Merck & Co., Inc., most
recently serving as President of the company’s Human Health
Intercontinental Division. He previously held the position of
President of Human Health Europe, Middle East/Africa and Worldwide
Human Health Marketing for Merck.
Mr. Wold-Olsen currently sits on the boards of directors of
three Danish-based companies. He serves as Chairman of both
Lundbeck A/S, a pharmaceutical company focused in the field of
central nervous system disorders, and GN Store Nord A/S, which
develops and commercializes hearing aids and headsets. He also
serves on the board of Exiqon A/S, a biotech company focused on the
development of research and diagnostic products. Mr. Wold-Olsen is
also a member of the board of the Medicines for Malaria Venture
(MMV), a non-profit initiative dedicated to the discovery,
development and delivery of new medicines for the treatment of
malaria.
“We have had the benefit of Per Wold-Olsen’s expertise for the
past several years through his role as a member and chair of
Gilead’s Health Policy Advisory Board and we are now very pleased
to welcome him to Gilead’s Board of Directors,” said John Martin,
PhD, Chairman and Chief Executive Officer, Gilead Sciences. “His
depth of experience in the pharmaceutical industry and specifically
his knowledge of international policy, regulatory and commercial
practices and challenges will be of great value to Gilead and to
our Board.”
About Gilead
Sciences
Gilead Sciences is a biopharmaceutical company that discovers,
develops and commercializes innovative therapeutics in areas of
unmet medical need. The company’s mission is to advance the care of
patients suffering from life-threatening diseases worldwide.
Headquartered in Foster City, California, Gilead has operations in
North America, Europe and Australia.
For more information on Gilead
Sciences, please visit the company's website at www.gilead.com or
call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Jun 2024 to Jul 2024
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Jul 2023 to Jul 2024